Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in NVS — Novartis AG

CIK 1423053 MIAMI, FL
Back to NVS Full portfolio

Position in NVS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$50,277,029
+$50,277,029 QoQ
Shares Held
320,808
Ownership
0.017%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#59
of 1,603 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVS Over Time

Shares Held

Position Value (USD)

Derivatives in NVS

reported options exposure · as of Jun 30, 2026
CallValue
$75,962,184
CallShares
484,700
PutValue
$35,857,536
PutShares
228,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $3,979,998,649 across 21 Drug Manufacturers - General names. NVS ranks #13 (1.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 945,456 $1,134,008,383
2 ABBV
AbbVie Inc.
 3,169,783 $797,644,194
3 GILD
Gilead Sciences, Inc.
 3,480,444 $439,719,294
4 JNJ
Johnson & Johnson
 1,500,832 $381,166,302
5 AMGN
Amgen Inc
 703,984 $254,926,685
6 MRK
Merck & Co., Inc.
 1,933,667 $248,476,209
7 AZN
Astrazeneca PLC
 970,043 $183,939,553
8 PFE
Pfizer Inc
 6,191,186 $149,083,758

All Filings in NVS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $35,857,536 228,800
2026-06-30 $50,277,029 320,808
2026-06-30 $75,962,184 484,700
2026-03-31 $109,170,425 714,700
2026-03-31 $16,894,150 110,600
2025-12-31 $61,241,854 444,200
2025-12-31 $25,974,708 188,400
2025-09-30 $52,629,696 410,400
2025-09-30 $22,980,608 179,200
2025-06-30 $44,519,579 367,900
2025-06-30 $15,404,573 127,300
2025-03-31 $9,542,688 85,600
2025-03-31 $119,014,487 1,067,586
2025-03-31 $32,574,456 292,200
2024-12-31 $57,236,574 588,188
2024-12-31 $34,360,161 353,100
2024-12-31 $25,378,448 260,800
2024-09-30 $20,954,458 182,181
2024-09-30 $12,410,658 107,900
2024-09-30 $45,501,912 395,600
2024-06-30 $8,782,950 82,500
2024-06-30 $34,173,660 321,000
2024-06-30 $26,248,884 246,561
2024-03-31 $43,954,112 454,400
2024-03-31 $54,370,481 562,085
2024-03-31 $11,017,547 113,900
2023-12-31 $64,459,248 638,400
2023-12-31 $44,432,352 440,055
2023-12-31 $27,968,690 277,000
2023-09-30 $64,232,916 630,600
2023-09-30 $17,356,944 170,400
2023-06-30 $83,906,665 831,500
2023-06-30 $167,611 1,661
2023-06-30 $45,661,775 452,500
2023-03-31 $16,008 174
2023-03-31 $86,802,000 943,500
2023-03-31 $40,544,400 440,700
2022-12-31 $79,942,464 881,200
2022-12-31 $147,501,648 1,625,900
2022-12-31 $3,788,920 41,765
2022-09-30 $55,988,966 736,600
2022-09-30 $86,879,430 1,143,000
2022-09-30 $10,654,548 140,173
2022-06-30 $58,114,375 687,500
2022-06-30 $5,274,249 62,395
2022-06-30 $65,130,365 770,500
2022-03-31 $38,917,125 443,500
2022-03-31 $63,258,975 720,900
2022-03-31 $376,447 4,290
2021-12-31 $68,681,444 785,200

Report a Problem

Category
Description
Email (optional, for follow-up)